Point of Care Diagnostics Market

Point of Care Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase(OTC, Prescription), Sample (Blood, Urine), User (Pharmacy, Hospital, Homecare) - Global Forecast to 2027

Report Code: MD 2702 Dec, 2022, by marketsandmarkets.com

The global point of care diagnostics market in terms of revenue was estimated to be worth $45.4 billion in 2022 and is poised to reach $75.5 billion by 2027, growing at a CAGR of 10.7% from 2022 to 2027. In the latest edition of the report, new product and sample segments have been added. The updated report will have a segment dedicated to providing a detailed understanding of different types of point of care products and samples. The growth of this market can be attributed to the high prevalence of respiratory diseases such as influenza, cardiac diseases, and infectious diseases (where point of care tests can greatly improve the management of these diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse). Furthermore, with the increasing availability of point of care testing products via online platforms, supportive government policies, and an increase in the number of CLIA-waived point of care tests, healthcare decentralisation and greater investments and funding for product development are expected to accelerate the growth of the point of care diagnostics market in the coming years.

However, factors such as pricing pressure owing to reimbursement cuts and budget constraints are expected to hamper the growth of the point of care diagnostics market during the forecast period.

Point of Care Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Point of Care Diagnostics Market Dynamics

Drivers: increasing prevalence of infectious diseases

Point of care tests with high sensitivity and specificity allow for rapid diagnosis and treatment of these highly infectious diseases. The prevalence of infectious diseases such as HIV, hepatitis, influenza, and tuberculosis is likely to boost the demand for point of care diagnostics for the rapid detection of infectious diseases. Listed below are important statistics related to major infectious diseases in developing countries:

  • According to the National Aids Control Organization (NACO), in 2021, approximately 2.40 million people in India were infected with HIV. Of the total HIV-infected population, 45% were women, and 2% were children under the age of 12.
  • According to the WHO Global TB Report 2021, of the 1.7 billion global population infected with TB, around 587 million people with TB reside in Southeast Asia (SEA).

Opportunities: Point of care tests with multiplexing capabilities.

Companies are trying to develop Point of care devices that can run multiple analytes on a single device. These devices can simultaneously measure multiple analytes on the same cartridge, which is known as multiplexing. Multiplex Point of care tests offer several advantages over widely adopted singleplex tests, such as increased efficiency at lower costs, greater output per sample, and higher throughput. These benefits will aid in the development of more precise and detailed diagnostics as well as the advancement of personalised medicine. Some examples of multiplexed devices include: The Triage 8 Panel for Drugs of Abuse from Alere is an immunoassay that determines the major metabolites of drugs of abuse and provides results in 10 minutes. The commercialization of such cost-effective and advanced multiplex Point of care tests will offer new growth opportunities for market players.

Restraints: pricing pressure owing to reimbursement cuts and budget constraints.

The pricing pressure due to reimbursement cuts and a lack of sufficient budgets has impacted the growth of the global point of care diagnostics market. In France, all the cost of patient care is rolled into one prospective payment under the Diagnosis Related Group (DRG) system, making reimbursement a negligible factor. In the country, the reimbursement for diabetes technologies in outpatient settings is based on a tariff system.

Moreover, the expenditure on general-use medical devices is reported to be stagnating owing to the decrease in the number of healthcare products eligible for reimbursement, making it a challenging factor for manufacturers to support prices as competition intensifies. This factor is expected to pose a key challenge to the growth of the global point of care diagnostics market in the coming years.

In 2021, the Glucose Monitoring Product segment accounted for a sizable portion of the global Point of Care Diagnostics market by product type.

The rising prevalence of diabetes and increased patient awareness about the availability of point of care testing in the market are anticipated to propel the demand for glucose monitoring products during the forecast period. According to the IDF Diabetes Atlas, the number of people living with diabetes will increase from 425 million in 2017 to 642 million by 2040.

The number of companies focusing on the development of innovative self-monitoring glucose meters, such as Medtronic's Guardian Sensor 3—a diagnostic chip that automatically monitors health—and Roche's Accu-Chek Blood Glucose Monitoring System with wireless connectivity and app support—is anticipated to promote the growth potential of this segment in the coming years.

The lateral flow assays segment, by platform type, accounted for the largest share of the global point of care diagnostics market in 2021.

The rapid adoption of LFA testing products in home care settings, the rising focus of players on the development of innovative LFA-based point of care devices, and the increasing awareness about the advantages of lateral flow assay-based point of care tests as a replacement for lengthy laboratory procedures and the lower cost associated with this procedure over conventional laboratory procedures are anticipated to boost the growth of the lateral flow assays segment during the forecast period.

The home care and self-testing segments are expected to have the highest CAGR of the point of care diagnostics market in terms of end users.

The home care and self-testing segment is projected to register the highest CAGR during the forecast period. The end users in this segment include patients and emergency response personnel who use monitoring devices in home settings. Devices such as blood glucose meters, blood pressure monitors, HIV test kits, pregnancy test kits, and respiratory infection test kits are prominently used in this segment. Ease of usage, lower cost, and increasing accessibility of advanced self-testing kits are some of the key factors supporting the increased uptake of home testing kits. Several market players and government organisations are entering into joint ventures, partnerships, and collaborations to develop innovative and cost-effective products suitable for home care requirements, further supporting the growth of the home care and self-testing segments in the near future.

In July 2022, the Clinton Health Access Initiative (CHAI), MedAccess, and Wondfo Biotech Company entered into a strategic partnership with the aim of providing the HIV self-test for USD 1 to the public sector in low- and middle-income countries. This initiative will increase the accessibility of affordable HIV self-testing globally.

Point of Care Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The Asia Pacific market is expected to grow at the highest CAGR of the point of care diagnostics market during the forecast period.

The market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share of the point of care diagnostics market. The rising prevalence of lifestyle diseases, government initiatives to support the wider adoption of point of care diagnostics, and the strong presence of key players in the region are anticipated to support the growth of the North American point of care diagnostics market.

Asia Pacific is projected to register the highest growth during the forecast period, owing to the rising number of hospitals and clinical diagnostics laboratories, growth in the patient population, the emergence of new rapid test kit manufacturers, increasing healthcare expenditure, and growing collaborations among players.

Prominent players in the point of care diagnostics market are Abbott Laboratories (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (a Werfen Company) (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux S.A. (France).

Abbott:

Abbott Laboratories is the leading player in the point of care diagnostics market. The strong focus on strengthening its brand presence and continuous investments in R&D to introduce novel products and improve its existing product line and processes are expected to help Abbott witness significant growth in the point-of-care diagnostics market during the forecast period. To expand its global diagnostics presence and leadership in the point-of-care diagnostics market, the company acquired Alere, Inc. in October 2017, gaining access to new channels and Alere's high-quality products.

Point of Care Diagnostics Market Report Scope

Report Metric

Details

Market Revenue in 2022

$45.4 billion

Estimated Value by 2027

$75.5 billion

Growth Rate

Poised to grow at a CAGR of 10.7%

Largest Share Segments

  • The infectious disease testing products
  • The Lateral Flow Assays segment
  • The OTC Testing Products segment

Market Report Segmentation

Product, Platform, Mode of Purchase, Sample, End User, and Region

Market Drivers

  • Increasing prevalence of infectious diseases

Market Opportunities

  • POC tests with multiplexing capabilities

Geographies covered

North America, Europe, APAC, MEA, and Latin America

This research report categorizes point of care diagnostics market into the following segments and sub-segments:

By Product

  • COVID-19 test products
  • Glucose Monitoring Products
    • Strips
    • Meters
    • Lancets & Lancing Devices
  • Cardiometabolic Monitoring Products
    • Point-of-care and rapid diagnostics Products
    • Blood Gas/Electrolyte Testing Products
    • HbA1c Testing Products
  • Infectious Disease Testing Products
    • Influenza Testing Products
    • HIV Testing Products
    • Hepatitis C Testing Products
    • Influenza Testing Products
    • Sexually Transmitted Disease Testing Products
      • Syphilis Testing Products
      • Human Papillomavirus (HPV) Testing Products
      • Chlamydia Trachomatis Testing Products
      • Herpes simplex virus (HSV) Testing Products
    • Healthcare-associated Infection Testing Products
    • Respiratory Infection Testing Products
    • Tuberculosis (TB) Testing Products
    • Clostridium Difficile Infection (CDI) Testing Products
    • Tropical Disease Testing Products
    • Other Infectious Disease Testing Products
  • Coagulation Monitoring Products
    • PT/INR Testing
    • ACT/APTT
  • Pregnancy & Fertility Testing Products
    • Pregnancy Testing Products
    • Fertility Testing Products
  • Tumor/Cancer Marker Testing Products
  • Urinalysis Testing Products
  • Cholesterol Testing Products
  • Hematology Testing Products
  • Thyroid Stimulating Hormone (TSH) Testing Products
  • Drugs-of-abuse Testing Products
  • Fecal Occult Testing Products
  • Other POC Products

By Platform

  • Lateral Flow Assays
  • Dipsticks
  • Microfluidics
  • Molecular Diagnostics
    • Polymerase Chain Reaction(PCR)
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Other Molecular Diagnostic Technologies
  • Immunoassays

By Mode of Purchase

  • Prescription-based Products
  • OTC Products

By Sample

  • Blood
  • Urine
  • Nasal and Oropharyngeal Swabs
  • Other Samples

By End User

  • Clinical Laboratories
  • Ambulatory Care Facilities and Physician Offices
  • Pharmacies, retail clinics, & E-comm. Platforms
  • Hospitals, Critical Care Centers, Urgent care centers
  • Home Care & Self Testing
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • RoLATAM
  • Middle East & Africa

Recent Developments

  • In May 2022, QuantuMDx announced the launch of its new respiratory panel test; Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay.
  • In March 2022, Boditech Med entered in strategic partnership with Novo Integrated Sciences, Inc. with an aim to expand its biomarker based rapid testing product line across North America
  • In January 2022, Roche launched its Cobas Pulse System in select countries accepting the CE Mark. This is Roche Diagnostics’ newest generation of connected point-of-care solutions for professional blood glucose management.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 48)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
    1.3 STUDY SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 GEOGRAPHIC SCOPE
           1.3.3 INCLUSIONS AND EXCLUSIONS
           1.3.4 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 53)
    2.1 RESEARCH DATA
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                               FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                               FIGURE 3 POINT OF CARE DIAGNOSTICS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION
          FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION
                    FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL MARKET
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
           2.4.1 RESEARCH ASSUMPTIONS
           2.4.2 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 63)
    FIGURE 7 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 8 GLOBAL MARKET, BY PLATFORM, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 GLOBAL MARKET, BY MODE OF PURCHASE, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 67)
    4.1 POINT OF CARE AND RAPID DIAGNOSTICS MARKET OVERVIEW
          FIGURE 12 RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET
    4.2 GLOBAL MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
          FIGURE 13 GLUCOSE MONITORING PRODUCTS SEGMENT WILL DOMINATE MARKET IN 2027
    4.3 GLOBAL MARKET SHARE, BY MODE OF PURCHASE (2022)
          FIGURE 14 OTC TESTING PRODUCTS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE IN 2022
    4.4 GLOBAL MARKET SHARE, BY PLATFORM, 2022 VS. 2027
          FIGURE 15 LATERAL FLOW ASSAYS WILL CONTINUE TO DOMINATE MARKET IN 2027
    4.5 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 71)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 17 POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 High prevalence of infectious diseases
                                FIGURE 18 HIV INFECTION, BY REGION, 2021
                    5.2.1.2 Increasing incidence of target conditions
                    5.2.1.3 Supportive government policies
                    5.2.1.4 Dearth of skilled laboratory technicians
                    5.2.1.5 Rising number of CLIA-waived POC tests
                                TABLE 1 RECENT WAIVERS FOR PRODUCTS
           5.2.2 RESTRAINTS
                    5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints
                    5.2.2.2 Stringent regulatory policies
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                    5.2.3.2 Healthcare decentralization
                    5.2.3.3 Increasing provider awareness about novel technologies
                    5.2.3.4 POC tests with multiplexing capabilities
                    5.2.3.5 Growing investments and funding for product development
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of alignment with definitive central lab methods
                    5.2.4.2 Inadequate adoption of POC devices in professional settings
                    5.2.4.3 Reluctance to change existing diagnostic practices
                    5.2.4.4 Premium pricing of novel platforms
    5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS
           5.3.1 SEPSIS BIOMARKERS
           5.3.2 STROKE/CARDIAC MARKERS
           5.3.3 THYROID TESTING
           5.3.4 DNA TESTING
           5.3.5 ENDOCRINE TESTING
           5.3.6 RESPIRATORY DIAGNOSTICS
    5.4 REGULATORY LANDSCAPE
          TABLE 2 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
           5.4.1 KEY REGULATORY GUIDELINES
                    5.4.1.1 US
                                FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.2 Canada
                                FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.3 Europe
                                FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.4 Japan
                                FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.5 China
                                TABLE 3 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.4.1.6 India
                                FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.7 Brazil
                                FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    5.5 VALUE CHAIN ANALYSIS
          FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES
    5.6 SUPPLY CHAIN ANALYSIS
           5.6.1 PROMINENT COMPANIES
           5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
           5.6.3 END USERS
                    FIGURE 26 SUPPLY CHAIN ANALYSIS
    5.7 PRICING TREND ANALYSIS
          TABLE 4 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2021 (USD)
          TABLE 5 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2021 (USD)
          TABLE 6 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2021 (USD)
    5.8 PORTER’S FIVE FORCES
           5.8.1 OVERVIEW
                    TABLE 7 POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.2 BARGAINING POWER OF BUYERS
           5.8.3 BARGAINING POWER OF SUPPLIERS
           5.8.4 THREAT OF NEW ENTRANTS
           5.8.5 THREAT OF SUBSTITUTES
           5.8.6 INTENSITY OF COMPETITIVE RIVALRY
    5.9 PATENT ANALYSIS
          FIGURE 27 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012–NOVEMBER 2022)
          FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012–NOVEMBER 2022)
          FIGURE 29 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS)
    5.10 KEY CONFERENCES AND EVENTS
          TABLE 8 GLOBAL MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS, 2021–2023
    5.11 CASE STUDY
           5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I
                     TABLE 9 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS
                     FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.12.1 KEY STAKEHOLDERS
                     FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS
                     TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)
    5.13 KEY BUYING CRITERIA
           TABLE 11 KEY BUYING CRITERIA FOR PRODUCTS

6 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 98)
    6.1 INTRODUCTION
          TABLE 12 GLOBAL MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 GLUCOSE MONITORING PRODUCTS
          TABLE 13 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 14 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
          TABLE 15 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
          TABLE 16 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
          TABLE 17 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
          TABLE 18 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.2.1 STRIPS
                    6.2.1.1 Strips make blood glucose testing easy and hassle-free
                                TABLE 19 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.2 METERS
                    6.2.2.1 Extremely helpful in monitoring blood glucose levels and adjusting therapeutic regimens
                                TABLE 20 GLUCOSE MONITORING METERS MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.3 LANCETS AND LANCING DEVICES
                    6.2.3.1 Lancets and lancing devices segment to register lower growth in glucose monitoring products market
                                TABLE 21 GLUCOSE MONITORING LANCETS AND LANCING DEVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3 COVID-19 TESTING PRODUCTS
           6.3.1 COVID-19 PANDEMIC ACCELERATED DEMAND FOR POC/RAPID DIAGNOSTIC PRODUCTS
                    TABLE 22 POINT OF CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 23 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 24 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 25 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 26 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.4 CARDIOMETABOLIC MONITORING PRODUCTS
          TABLE 27 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 28 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
          TABLE 29 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
          TABLE 30 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
          TABLE 31 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
          TABLE 32 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.4.1 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
                    6.4.1.1 Technological advancements in blood gas/electrolyte products to drive market
                                TABLE 33 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.4.2 CARDIAC MARKER TESTING PRODUCTS
                    6.4.2.1 Rising prevalence of heart diseases and development of new POC test to support market growth
                                TABLE 34 GLOBAL MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.4.3 HBA1C TESTING PRODUCTS
                    6.4.3.1 Government initiatives promoting regular use of HbA1c testing
                                TABLE 35 GLOBAL MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.5 INFECTIOUS DISEASE TESTING PRODUCTS
          TABLE 36 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 37 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
          TABLE 38 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
          TABLE 39 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
          TABLE 40 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
          TABLE 41 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.1 HIV TESTING PRODUCTS
                    6.5.1.1 Rising prevalence of HIV to drive market
                                 TABLE 42 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 43 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 44 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 45 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.2 RESPIRATORY INFECTION TESTING PRODUCTS
                    6.5.2.1 POCT products for diagnosis of respiratory infections offer lower sensitivity
                                 TABLE 46 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 47 GLOBAL MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 48 GLOBAL MARKET FOR RESPIRATORY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 49 GLOBAL MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.3 HEPATITIS C TESTING PRODUCTS
                    6.5.3.1 Central and East Asia among highly affected regions by hepatitis C
                                 TABLE 50 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 51 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 52 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 53 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
                    6.5.4.1 Rising prevalence of HAIs to drive market
                                 TABLE 54 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 55 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 56 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 57 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.5 INFLUENZA TESTING PRODUCTS
                    6.5.5.1 Rising influenza prevalence to drive demand for influenza testing products
                                 TABLE 58 POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 59 GLOBAL MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 60 GLOBAL MARKET FOR INFLUENZA TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 61 GLOBAL MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.6 TROPICAL DISEASE TESTING PRODUCTS
                    6.5.6.1 Increasing government funding for use of POC in tropical disease testing to support market growth
                                 TABLE 62 GLOBAL MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 63 GLOBAL MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 64 GLOBAL MARKET FOR TROPICAL DISEASES PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 65 GLOBAL MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
                    TABLE 66 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 67 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 68 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 69 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 70 GLBOAL MARKET FOR STD TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
                    6.5.7.1 Syphilis testing products
                               6.5.7.1.1 Introduction of rapid tests for syphilis to support market growth
                                              TABLE 71 POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
                    6.5.7.2 Human papillomavirus (HPV) testing products
                               6.5.7.2.1 Technological advancements to aid market growth
                                              TABLE 72 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
                    6.5.7.3 Chlamydia trachomatis testing products
                               6.5.7.3.1 Growing incidence of chlamydia and rising awareness among patients to drive market
                                              TABLE 73 GLOBAL MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
                    6.5.7.4 Herpes simplex virus (HSV) testing products
                               6.5.7.4.1 Increasing incidence of HSV to boost adoption of rapid tests
                                              TABLE 74 GLOBAL MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.8 TUBERCULOSIS (TB) TESTING PRODUCTS
                    6.5.8.1 Rising prevalence of TB and initiatives by governments to propel demand for rapid TB tests
                                 TABLE 75 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 76 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 77 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 78 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.9 CLOSTRIDIUM DIFFICILE INFECTION (CDI) TESTING PRODUCTS
                    6.5.9.1 Increasing cases of CDI infections among hospitalized patients to support market growth
                                 TABLE 79 GLOBAL MARKET FOR CDI TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                                 TABLE 80 GLOBAL MARKET FOR CDI TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                                 TABLE 81 POINT OF CARE DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                                 TABLE 82 GLOBAL MARKET FOR CDI TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.5.10 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
                    TABLE 83 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 84 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 85 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 86 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.6 COAGULATION MONITORING PRODUCTS
          TABLE 87 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 88 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
          TABLE 89 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
          TABLE 90 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
          TABLE 91 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
          TABLE 92 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.6.1 PT/INR TESTING PRODUCTS
                    6.6.1.1 Most commonly used coagulation monitoring method
                                TABLE 93 GLOBAL MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.6.2 ACT/APTT TESTING PRODUCTS
                    6.6.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth
                                TABLE 94 GLOBAL MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.7 PREGNANCY AND FERTILITY TESTING PRODUCTS
          TABLE 95 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 96 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
          TABLE 97 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
          TABLE 98 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
          TABLE 99 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
          TABLE 100 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.7.1 PREGNANCY TESTING PRODUCTS
                    6.7.1.1 Rising inclination toward home testing to support market growth
                                TABLE 101 GLOBAL MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
           6.7.2 FERTILITY TESTING PRODUCTS
                    6.7.2.1 Increasing awareness of fertility testing to drive market
                                TABLE 102 GLOBAL MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.8 TUMOR/CANCER MARKER TESTING PRODUCTS
           6.8.1 INCREASING PREVALENCE OF CANCER TO BOOST DEMAND FOR RAPID TESTING
                    TABLE 103 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 104 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 105 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 106 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 107 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.9 URINALYSIS TESTING PRODUCTS
           6.9.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS TO DRIVE MARKET
                    TABLE 108 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 109 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 110 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 111 POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 112 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.10 CHOLESTEROL TESTING PRODUCTS
           6.10.1 RISING OBESITY LEVELS TO DRIVE ADOPTION OF CHOLESTEROL TESTING PRODUCTS
                    TABLE 113 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 114 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 115 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 116 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 117 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.11 HEMATOLOGY TESTING PRODUCTS
           6.11.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS TO IMPEDE MARKET GROWTH
                    TABLE 118 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 119 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 120 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 121 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 122 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.12 DRUGS-OF-ABUSE TESTING PRODUCTS
           6.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO BOOST DEMAND FOR TESTING
                    TABLE 123 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 124 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 125 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 126 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 127 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.13 FECAL OCCULT TESTING PRODUCTS
           6.13.1 LACK OF PROPER TRAINING FOR FECAL OCCULT TESTING TO HAMPER MARKET GROWTH
                    TABLE 128 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 129 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 130 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 131 POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 132 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.14 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS
           6.14.1 RISING CASES OF THYROID TO BOOST ADOPTION OF RAPID TESTS
                    TABLE 133 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
                    TABLE 134 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                    TABLE 135 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
                    TABLE 136 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
                    TABLE 137 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
    6.15 OTHER PRODUCTS
          TABLE 138 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
          TABLE 139 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
          TABLE 140 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
          TABLE 141 OTHER GLOBAL MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
          TABLE 142 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)

7 POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (Page No. - 177)
    7.1 INTRODUCTION
          TABLE 143 GLOBAL MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
    7.2 LATERAL FLOW ASSAYS
           7.2.1 INCREASING ADOPTION OF LFA TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET
                    TABLE 144 GLOBAL MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2020–2027 (USD MILLION)
    7.3 IMMUNOASSAYS
           7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH
                    TABLE 145 GLOBAL MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION)
    7.4 MICROFLUIDICS
           7.4.1 EMERGING PLATFORM IN POC DIAGNOSTICS MARKET
                    TABLE 146 GLOBAL MARKET FOR MICROFLUIDICS, BY REGION, 2020–2027 (USD MILLION)
    7.5 DIPSTICKS
           7.5.1 DIPSTICKS HELP IN ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS
                    TABLE 147 GLOBAL MARKET FOR DIPSTICKS, BY REGION, 2020–2027 (USD MILLION)
    7.6 MOLECULAR DIAGNOSTICS
          TABLE 148 GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
          TABLE 149 GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
           7.6.1 RT-PCR
                    7.6.1.1 COVID-19 testing boosted demand for RT-PCR technology
                                TABLE 150 GLOBAL MARKET FOR RT-PCR, BY REGION, 2020–2027 (USD MILLION)
           7.6.2 INAAT
                    7.6.2.1 Cost benefits of INAAT to drive adoption
                                TABLE 151 GLOBAL MARKET FOR INAAT, BY REGION, 2020–2027 (USD MILLION)
           7.6.3 OTHER TECHNOLOGIES
                    TABLE 152 GLOBAL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)

8 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (Page No. - 187)
    8.1 INTRODUCTION
          TABLE 153 GLOBAL MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
    8.2 OTC TESTING PRODUCTS
           8.2.1 RISING FOCUS ON HOME CARE TO BOOST DEMAND FOR OTC TESTING PRODUCTS
                    TABLE 154 OTC POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.3 PRESCRIPTION-BASED TESTING PRODUCTS
           8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT TO DRIVE MARKET
                    TABLE 155 PRESCRIPTION-BASED POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)

9 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE (Page No. - 191)
    9.1 INTRODUCTION
          TABLE 156 GLOBAL MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
    9.2 BLOOD
           9.2.1 RISING APPLICATION OF BLOOD SAMPLES IN DETECTION OF VARIOUS DISEASES TO DRIVE GROWTH
                    TABLE 157 GLOBAL MARKET FOR BLOOD SAMPLES, BY REGION, 2020–2027 (USD MILLION)
    9.3 URINE
           9.3.1 GROWING PREVALENCE OF KIDNEY DISORDERS TO BOOST MARKET GROWTH
                    TABLE 158 GLOBAL MARKET FOR URINE SAMPLES, BY REGION, 2020–2027 (USD MILLION)
    9.4 NASAL AND OROPHARYNGEAL SWABS
           9.4.1 INCREASING PREVALENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET GROWTH
                    TABLE 159 GLOBAL MARKET FOR NASAL AND OROPHARYNGEAL SWABS, BY REGION, 2020–2027 (USD MILLION)
    9.5 OTHER SAMPLES
          TABLE 160 GLOBAL MARKET FOR OTHER SAMPLES, BY REGION, 2020–2027 (USD MILLION)

10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER (Page No. - 196)
     10.1 INTRODUCTION
             TABLE 161 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.2 CLINICAL LABORATORIES
             10.2.1 IMPROVEMENTS IN CLINICAL DIAGNOSTICS AND TESTING TECHNOLOGIES TO DRIVE MARKET
                        TABLE 162 GLOBAL MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
     10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES
             10.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE—MAJOR FACTORS DRIVING MARKET GROWTH
                        TABLE 163 GLOBAL MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2020–2027 (USD MILLION)
     10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS
             10.4.1 CONVENIENCE AND EASE OF EXPERT ACCESS TO DRIVE MARKET
                        TABLE 164 GLOBAL MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2020–2027 (USD MILLION)
     10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
             10.5.1 HOSPITALS LARGEST END USERS OF POC DIAGNOSTICS
                        TABLE 165 GLOBAL MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2020–2027 (USD MILLION)
     10.6 HOME CARE AND SELF-TESTING
             10.6.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE TO DRIVE MARKET
                        TABLE 166 GLOBAL MARKET FOR HOME CARE AND SELF-TESTING, BY REGION, 2020–2027 (USD MILLION)
     10.7 OTHER END USERS
             TABLE 167 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION (Page No. - 203)
     11.1 INTRODUCTION
             TABLE 168 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 32 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
             TABLE 169 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 170 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 171 NORTH AMERICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 172 NORTH AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 173 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 174 NORTH AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 175 NORTH AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 176 NORTH AMERICA: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
             TABLE 177 NORTH AMERICA: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
             TABLE 178 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 179 NORTH AMERICA: MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
             11.2.1 US
                        11.2.1.1 US dominates North American POC diagnostics market
                                      TABLE 180 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 181 US: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 182 US: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 183 US: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 184 US: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Rising government initiatives to support growth of POC diagnostics market in Canada
                                      TABLE 185 CANADA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 186 CANADA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 187 CANADA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 188 CANADA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 189 CANADA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
     11.3 EUROPE
             TABLE 190 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 191 EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 192 EUROPE: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 193 EUROPE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 194 EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 195 EUROPE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 196 EUROPE: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 197 EUROPE: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
             TABLE 198 EUROPE: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
             TABLE 199 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 200 EUROPE: MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Largest market for POC diagnostics in Europe
                                      TABLE 201 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 202 GERMANY: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 203 GERMANY: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 204 GERMANY: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 205 GERMANY: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 Growing public-private collaborations for product development to drive market
                                      TABLE 206 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 207 FRANCE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 208 FRANCE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 209 FRANCE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 210 FRANCE: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Benefits of POC diagnostics to support market growth
                                      TABLE 211 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 212 UK: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 213 UK: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 214 UK: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 215 UK: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Rising prevalence of chronic diseases to drive demand for POC diagnostics
                                      TABLE 216 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 217 ITALY: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 218 ITALY: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 219 ITALY: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 220 ITALY: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Rising geriatric population to support market growth
                                      TABLE 221 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 222 SPAIN: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 223 SPAIN: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 224 SPAIN: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 225 SPAIN: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 226 REST OF EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 227 REST OF EUROPE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 228 REST OF EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 229 REST OF EUROPE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 230 REST OF EUROPE: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
     11.4 ASIA PACIFIC
             FIGURE 33 ASIA PACIFIC: MARKET SNAPSHOT
             TABLE 231 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 232 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 233 ASIA PACIFIC: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 234 ASIA PACIFIC: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 235 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 236 ASIA PACIFIC: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 237 ASIA PACIFIC: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 238 ASIA PACIFIC: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
             TABLE 239 ASIA PACIFIC: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
             TABLE 240 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 241 ASIA PACIFIC: MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Japan to dominate Asia Pacific POC diagnostics market during forecast period
                                      TABLE 242 JAPAN: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 243 JAPAN: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 244 JAPAN: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 245 JAPAN: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 246 JAPAN: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Rising investments by market players and government to drive market
                                      TABLE 247 CHINA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 248 CHINA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 249 CHINA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 250 CHINA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 251 CHINA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 High burden of chronic diseases to support market growth
                                      TABLE 252 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 253 INDIA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 254 INDIA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 255 INDIA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 256 INDIA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Government initiatives to support adoption of point-of-care testing
                                      TABLE 257 AUSTRALIA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 258 AUSTRALIA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 259 AUSTRALIA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 260 AUSTRALIA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 261 AUSTRALIA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Increased funding and product development to propel market growth
                                      TABLE 262 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 263 SOUTH KOREA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 264 SOUTH KOREA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 265 SOUTH KOREA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 266 SOUTH KOREA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 267 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 268 REST OF ASIA PACIFIC: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 269 REST OF ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 270 REST OF ASIA PACIFIC: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 271 REST OF ASIA PACIFIC: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
     11.5 LATIN AMERICA
              TABLE 272 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
              TABLE 273 LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
              TABLE 274 LATIN AMERICA: POINT-OF-CARE AND aDIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 275 LATIN AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 276 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 277 LATIN AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 278 LATIN AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
              TABLE 279 LATIN AMERICA: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
              TABLE 280 LATIN AMERICA: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
              TABLE 281 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
              TABLE 282 LATIN AMERICA: MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Rising prevalence of diabetes to support market growth
                                      TABLE 283 BRAZIL: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 284 BRAZIL: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 285 BRAZIL: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 286 BRAZIL: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 287 BRAZIL: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 Rising prevalence of diabetes and cancer to drive market
                                      TABLE 288 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 289 MEXICO: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 290 MEXICO: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 291 MEXICO: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 292 MEXICO: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 293 REST OF LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 294 REST OF LATIN AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 295 REST OF LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 296 REST OF LATIN AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 297 REST OF LATIN AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 RISING PREVALENCE OF HIV TO DRIVE MARKET
                        TABLE 298 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 299 MIDDLE EAST & AFRICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 300 MIDDLE EAST & AFRICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 301 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 302 MIDDLE EAST & AFRICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 303 MIDDLE EAST & AFRICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 304 MIDDLE EAST & AFRICA: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
                        TABLE 305 MIDDLE EAST & AFRICA: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
                        TABLE 306 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 307 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 289)
     12.1 INTRODUCTION
                        TABLE 308 OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019−2022)
     12.2 REVENUE SHARE ANALYSIS
             FIGURE 34 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
     12.3 MARKET SHARE ANALYSIS
             FIGURE 35 MARKET SHARE, BY KEY PLAYER, 2021
     12.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021)
             12.4.1 STARS
             12.4.2 EMERGING LEADERS
             12.4.3 PERVASIVE PLAYERS
             12.4.4 PARTICIPANTS
                        FIGURE 36 MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
     12.5 COMPETITIVE LEADERSHIP MAPPING: STARTUP/SME EVALUATION QUADRANT (2021)
             12.5.1 PROGRESSIVE COMPANIES
             12.5.2 RESPONSIVE COMPANIES
             12.5.3 DYNAMIC COMPANIES
             12.5.4 STARTING BLOCKS
                        FIGURE 37 MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS) (2021)
     12.6 COMPETITIVE BENCHMARKING
             12.6.1 FOOTPRINT ANALYSIS OF COMPANIES
                        TABLE 309 OVERALL FOOTPRINT OF COMPANIES
                        TABLE 310 PRODUCT FOOTPRINT OF COMPANIES
                        TABLE 311 REGIONAL FOOTPRINT OF COMPANIES
     12.7 COMPETITIVE SCENARIO
             12.7.1 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 312 MARKET: KEY PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–OCTOBER 2022)
             12.7.2 DEALS
                        TABLE 313 MARKET: KEY DEALS (JANUARY 2019–OCTOBER 2022)
             12.7.3 OTHER DEVELOPMENTS
                        TABLE 314 GLOBAL MARKET: OTHER KEY DEVELOPMENTS (JANUARY 2019–OCTOBER 2022)

13 COMPANY PROFILES (Page No. - 304)
     13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View)*
             13.1.1 ABBOTT LABORATORIES
                        TABLE 315 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             13.1.2 SIEMENS HEALTHINEERS AG
                        TABLE 316 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                        FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
             13.1.3 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 317 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
             13.1.4 QUIDEL CORPORATION
                        TABLE 318 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.5 DANAHER CORPORATION
                        TABLE 319 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.6 BECTON, DICKINSON AND COMPANY
                        TABLE 320 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             13.1.7 THERMO FISHER SCIENTIFIC
                        TABLE 321 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
             13.1.8 BIOMÉRIEUX S.A.
                        TABLE 322 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW
                        FIGURE 45 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2021)
             13.1.9 CHEMBIO DIAGNOSTICS, INC.
                        TABLE 323 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW
                        FIGURE 46 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2021)
             13.1.10 EKF DIAGNOSTICS
                        TABLE 324 EKF DIAGNOSTICS: BUSINESS OVERVIEW
                        FIGURE 47 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2021)
             13.1.11 TRINITY BIOTECH PLC
                        TABLE 325 TRINITY BIOTECH PLC: BUSINESS OVERVIEW
                        FIGURE 48 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2021)
             13.1.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
                        TABLE 326 INSTRUMENTATION LABORATORY: BUSINESS OVERVIEW
             13.1.13 NOVA BIOMEDICAL
                        TABLE 327 NOVA BIOMEDICAL: BUSINESS OVERVIEW
             13.1.14 PTS DIAGNOSTICS
                        TABLE 328 PTS DIAGNOSTICS: BUSINESS OVERVIEW
             13.1.15 SEKISUI DIAGNOSTICS
                        TABLE 329 SEKISUI DIAGNOSTICS: BUSINESS OVERVIEW
             13.1.16 EUROLYSER DIAGNOSTICA GMBH
                        TABLE 330 EUROLYSER DIAGNOSTICA GMBH: BUSINESS OVERVIEW
             13.1.17 RESPONSE BIOMEDICAL
                        TABLE 331 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW
             13.1.18 ALFA SCIENTIFIC DESIGNS, INC.
                        TABLE 332 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW
             13.1.19 BODITECH MED INC.
                        TABLE 333 BODITECH MED INC.: BUSINESS OVERVIEW
             13.1.20 BTNX INC.
                        TABLE 334 BTNX INC.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS
             13.2.1 LIFESCAN IP HOLDINGS, LLC
             13.2.2 ASCENSIA DIABETES CARE
             13.2.3 FLUXERGY
             13.2.4 PRECISION BIOSENSOR, INC.
             13.2.5 ACON LABORATORIES, INC.
             13.2.6 A. MENARINI DIAGNOSTICS S.R.L.
             13.2.7 ORASURE TECHNOLOGIES, INC.
             13.2.8 MANKIND PHARMA
             13.2.9 TERUMO CORPORATION
             13.2.10 GRIFOLS, S.A.
             13.2.11 DIASORIN S.P.A.
             13.2.12 ACCUBIOTECH CO., LTD.
             13.2.13 MERIDIAN BIOSCIENCE
             13.2.14 BIOCARTIS
             13.2.15 GENESTAT MOLECULAR DIAGNOSTICS, LLC.

14 APPENDIX (Page No. - 390)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 CUSTOMIZATION OPTIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

The study involved four major activities to estimate the current size of the point of care diagnostics market. Extensive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Secondary Research

The secondary sources referred to in this research study include corporate filings (such as annual reports, SEC filings, investor presentations, and financial statements); research journals; press releases; and trade, business, and professional associations. Secondary sources were used to identify and collect useful information for this extensive and commercial study of the point of care diagnostics market. Secondary research was mainly used to obtain key information about the industry's total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, market trends, and critical developments by both the public and private organisations in the point of care diagnostics market.

The secondary sources referred to for this research study include government sources, independent or public sources, paid or private databases, and research databases, among others. Secondary data was collected and analysed to arrive at the overall market size of the point of care diagnostics market, which was further validated by primary research. Some of the key secondary sources consulted during the preparation of this report are listed below:

  • Governmental and intergovernmental sources and databases such as the World Health Organization (WHO), World Bank, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), and National Health Service (NHS), among others
  • Business and Research Articles: Springer Nature, The Lancet, PubMed, and the US National Library of Medicine, among others
  • Company sources include annual reports, SEC filings, regulatory filings, investor presentations, press releases, and financial statements, among others.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the point of care diagnostics market scenario. A significant number of primary interviews were conducted from the demand (such as hospital labs, reference labs, academic institutes, and point of care testing centers) and supply sides (such as product manufacturers, wholesalers, channel partners, and distributors). The primary respondents interviewed for this study include experts from the point of care diagnostics testing industry (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering point-of-care and rapid diagnostic testing products worldwide) and administrators and purchase managers of hospitals, general physicians, cardiologists, ambulatory care centers, and healthcare service providers.

Around 65% and 35% of primary interviews were conducted from the supply and demand sides, respectively. To validate the report's contents and fill gaps, a strong primary research methodology was used. Telephonic and e-mail communications were adopted to conduct interviews (questionnaires were designed and sent to primary participants as per their convenience).

The point of care diagnostics market comprises several stakeholders, such as diagnostic laboratories and point of care testing laboratories. The demand side of this market is characterised by the growing incidence of infectious diseases, diabetes, and cardiovascular diseases; a rapidly increasing geriatric population; growing funding from public and private organisations for research on rapid tests; and ongoing research for the development of novel point of care tests. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:

A breakdown of the primary respondents is provided below:

Point of Care Diagnostics Market Size

*C-level primaries include CEOs, CFOs, COOs, and VPs.

**Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue; as of 2021, Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 =

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the point-of-care and rapid diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Point of Care Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size during the above-mentioned estimation process, the global point-of-care and rapid diagnostics market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using the top-down approach.

Report Objectives

  • To define, describe, and forecast the point of care diagnostics market by Product, Platform, Mode of Purchase, Sample, End User, and Region
  • To provide detailed information about major factors influencing market growth (key drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and their contributions to the overall point of care diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the market value of various segments and sub-segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players active in the point-of-care and rapid diagnostics market and comprehensively analyze their global revenue shares and core competencies2
  • To track and analyze competitive market-specific developments such as product approvals & commercialization, agreements, partnerships, collaborations, acquisitions, and expansions in the point-of-care and rapid diagnostics   market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global point of care diagnostics market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Europe point of care diagnostics market into Belgium, Austria, the Czech Republic, Denmark, Greece, Poland, and Russia, among other
  • Further breakdown of the Rest of Asia Pacific point of care diagnostics market into New Zealand, Vietnam, the Philippines, Singapore, Malaysia, Thailand, and Indonesia among other
  • Further breakdown of the Latin American point of care diagnostics market into Argentina, Chile, Peru, and Colombia, among other
Report Code
MD 2702
Published ON
Dec, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Point of Care Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback